http://www.bizjournals.com/triangle/news/2016/07/19/where-gs...
> The fact is R&D isn't making drug prices high.
Neither are their SGA expenses. The two combined are just under half GSK's revenue.
Anyway, that's irrelevant to trying to score cheap points with a false equivalence.
http://www.bizjournals.com/triangle/news/2016/07/19/where-gs...